C07K 2317/80
Remaining in the cell, i.e. intracellular antibodies or intrabodies
Official title: remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
C07K2317/80 (Remaining in the cell, i.e. intracellular antibodies or intrabodies) appears on 117 US grants and 231 published applications in this corpus.
Search patents in C07K- Granted patents
- 117
- Published applications
- 231
- Assignees
- 146
- Inventors
- 448
- Latest grant
- 19 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 1 | 1 |
| 2003 | 2 | 2 |
| 2004 | 1 | 3 |
| 2005 | 0 | 9 |
| 2006 | 2 | 9 |
| 2007 | 4 | 8 |
| 2008 | 1 | 4 |
| 2009 | 1 | 7 |
| 2010 | 0 | 13 |
| 2011 | 2 | 5 |
| 2012 | 4 | 4 |
| 2013 | 6 | 10 |
| 2014 | 8 | 12 |
| 2015 | 9 | 11 |
| 2016 | 12 | 10 |
| 2017 | 6 | 12 |
| 2018 | 7 | 13 |
| 2019 | 1 | 9 |
| 2020 | 8 | 10 |
| 2021 | 8 | 15 |
| 2022 | 5 | 10 |
| 2023 | 4 | 5 |
| 2024 | 9 | 17 |
| 2025 | 9 | 15 |
| 2026 | 3 | 16 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Single chain intrabodies that alter huntingtin mutant degradation19 May 2026US 12,630,612 B2Vybion, Inc.
- Exosomes for target specific delivery and methods for preparing and delivering the same3 Feb 2026US 12,539,325 B2Ilias Biologics Inc.
- Chimeric receptor for use in whole-cell sensors for detecting analytes of interest6 Jan 2026US 12,517,124 B2Centre National de la Recherche Scientifique (CNRS)
- Single domain antibodies directed against intracellular antigens30 Dec 2025US 12,509,530 B2Singh Moelcular Medicine, LLC
- Targeting intracellular target-binding determinants with intracellular antibodies25 Nov 2025US 12,479,925 B2The United States Government as represented by the Department of Veterans Affairs
- Anti-pcna nanobodies, fusion proteins, and uses thereof24 Sep 2026US 2026/0285959 A1Hubei University
- Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators10 Sep 2026US 2026/0265414 A1Yale University
- Mitochondria as a targeted delivery platform3 Sep 2026US 2026/0256940 A1cellvie Inc.
- Chimeric receptor for use in whole-cell sensors for detecting analytes of interest27 Aug 2026US 2026/0251653 A1Centre National de la Recherche Scientifique (CNRS)
- Lipid Nanoparticle, Pharmaceutical Composition, and Method for Producing Lipid Nanoparticle13 Aug 2026US 2026/0232839 A1Japan Science and Technology Agency
Most cited
By later US patents
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- Methods for treatment of cancer216US 8,916,381 B1The Trustees of the University of Pennyslvania · 2014
- Compositions for treatment of cancer199US 8,975,071 B1The Trustees of the University of Pennsylvania · 2015
- Methods for treatment of cancer199US 9,101,584 B2The Trustees of the University of Pennsylvania · 2015